{"id":3761,"date":"2026-06-05T09:16:35","date_gmt":"2026-06-05T16:16:35","guid":{"rendered":"https:\/\/xpharma.com.cn\/?p=3761"},"modified":"2026-06-05T09:16:36","modified_gmt":"2026-06-05T16:16:36","slug":"otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process","status":"publish","type":"post","link":"https:\/\/xpharma.com.cn\/index.php\/news\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\/","title":{"rendered":"Otsuka Pharmaceutical\uff1aVoyxactSibeprenlimab\u00a0was approved through the priority review process."},"content":{"rendered":"\n<figure class=\"wp-block-image size-full is-resized\"><img fetchpriority=\"high\" decoding=\"async\" width=\"344\" height=\"146\" src=\"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/otsuka.jpg\" alt=\"Otsuka Pharmaceutical\" class=\"wp-image-2769\" style=\"object-fit:contain;width:420px;height:310px\" srcset=\"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/otsuka.jpg 344w, https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/otsuka-300x127.jpg 300w\" sizes=\"(max-width: 344px) 100vw, 344px\" \/><figcaption class=\"wp-element-caption\">Otsuka Pharmaceutical<\/figcaption><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The National Medical Products Administration (NMPA) recently granted conditional approval to Otsuka Pharmaceutical Co., Ltd. for Sibeprenlimab Injection (subcutaneous injection) (brand name: <strong>Voyxact<\/strong>) through a priority review and approval process. The drug is indicated for reducing proteinuria in adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. The approval of this product provides a new treatment option for relevant patients<a href=\"http:\/\/www.cnpharm.com\/c\/2026-06-05\/1098714.shtml\"><\/a><a href=\"https:\/\/finance.sina.com.cn\/wm\/2026-06-04\/doc-iniafvzs9312949.shtml\"><\/a><a href=\"https:\/\/m.cnpharm.com\/c\/2026-06-05\/1098704.shtml\"><\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Voyxact, approved in China for maintaining renal function in adult patients with primary IgA nephropathy, is the world&#8217;s first APRIL-targeting monoclonal antibody approved for marketing. The drug was originally developed by Vistera and acquired by Otsuka Pharmaceutical in 2018 for $430 million. Its mechanism precisely targets the core pathway of IgA nephropathy: by selectively binding and inhibiting APRIL activity, it reduces levels of pathogenic IgA and galactose-deficient Gd-IgA1, thereby delaying the progression of end-stage renal disease. The dosing regimen is convenient\u2014subcutaneous injection once every four weeks, which can be self-administered at home.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Buy Voyxact<strong>\uff08<\/strong>Sibeprenlimab\uff09\u00a0online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The National Medical Products Administration (NMPA) recently granted conditional approval to Otsuka Pharmaceutical Co., Ltd. for Sibeprenlimab Injection (subcutaneous injection) (brand name: Voyxact) through a priority review and approval process. The drug is indicated for reducing proteinuria in adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. The approval [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-3761","post","type-post","status-publish","format-standard","hentry","category-news"],"blocksy_meta":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Otsuka Pharmaceutical\uff1aVoyxactSibeprenlimab\u00a0was approved through the priority review process. - Xpharma China<\/title>\n<meta name=\"description\" content=\"Otsuka Pharmaceutical\uff1aVoyxactSibeprenlimab\u00a0was approved through the priority review process. - Xpharma China\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/xpharma.com.cn\/index.php\/news\/otsuka-pharmaceutical\uff1avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Otsuka Pharmaceutical\uff1aVoyxactSibeprenlimab\u00a0was approved through the priority review process. - Xpharma China\" \/>\n<meta property=\"og:description\" content=\"Otsuka Pharmaceutical\uff1aVoyxactSibeprenlimab\u00a0was approved through the priority review process. - Xpharma China\" \/>\n<meta property=\"og:url\" content=\"https:\/\/xpharma.com.cn\/index.php\/news\/otsuka-pharmaceutical\uff1avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\/\" \/>\n<meta property=\"og:site_name\" content=\"Xpharma China\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/61590027634719\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-05T16:16:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-05T16:16:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/otsuka.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"344\" \/>\n\t<meta property=\"og:image:height\" content=\"146\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"xpharmanews\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:site\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"xpharmanews\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\\\/\"},\"author\":{\"name\":\"xpharmanews\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\"},\"headline\":\"Otsuka Pharmaceutical\uff1aVoyxactSibeprenlimab\u00a0was approved through the priority review process.\",\"datePublished\":\"2026-06-05T16:16:35+00:00\",\"dateModified\":\"2026-06-05T16:16:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\\\/\"},\"wordCount\":204,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/otsuka.jpg\",\"articleSection\":[\"Approved News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\\\/#respond\"]}]},{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\\\/\",\"name\":\"Otsuka Pharmaceutical\uff1aVoyxactSibeprenlimab\u00a0was approved through the priority review process. - Xpharma China\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/otsuka.jpg\",\"datePublished\":\"2026-06-05T16:16:35+00:00\",\"dateModified\":\"2026-06-05T16:16:36+00:00\",\"description\":\"Otsuka Pharmaceutical\uff1aVoyxactSibeprenlimab\u00a0was approved through the priority review process. - Xpharma China\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\\\/#primaryimage\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/otsuka.jpg\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/otsuka.jpg\",\"width\":344,\"height\":146,\"caption\":\"Otsuka Pharmaceutical\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9875\",\"item\":\"https:\\\/\\\/xpharma.com.cn\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Otsuka Pharmaceutical\uff1aVoyxactSibeprenlimab\u00a0was approved through the priority review process.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"name\":\"Xpharma China - International Pharmaceutical wholesaler and retailer\",\"description\":\"Xpharma China\",\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/xpharma.com.cn\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\",\"name\":\"Xpharma China\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"width\":679,\"height\":166,\"caption\":\"Xpharma China\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/61590027634719\\\/\",\"https:\\\/\\\/x.com\\\/Xpharma007\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\",\"name\":\"xpharmanews\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"caption\":\"xpharmanews\"},\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/author\\\/xpharmanews\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Otsuka Pharmaceutical\uff1aVoyxactSibeprenlimab\u00a0was approved through the priority review process. - Xpharma China","description":"Otsuka Pharmaceutical\uff1aVoyxactSibeprenlimab\u00a0was approved through the priority review process. - Xpharma China","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/xpharma.com.cn\/index.php\/news\/otsuka-pharmaceutical\uff1avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\/","og_locale":"en_US","og_type":"article","og_title":"Otsuka Pharmaceutical\uff1aVoyxactSibeprenlimab\u00a0was approved through the priority review process. - Xpharma China","og_description":"Otsuka Pharmaceutical\uff1aVoyxactSibeprenlimab\u00a0was approved through the priority review process. - Xpharma China","og_url":"https:\/\/xpharma.com.cn\/index.php\/news\/otsuka-pharmaceutical\uff1avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\/","og_site_name":"Xpharma China","article_publisher":"https:\/\/www.facebook.com\/61590027634719\/","article_published_time":"2026-06-05T16:16:35+00:00","article_modified_time":"2026-06-05T16:16:36+00:00","og_image":[{"width":344,"height":146,"url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/otsuka.jpg","type":"image\/jpeg"}],"author":"xpharmanews","twitter_card":"summary_large_image","twitter_creator":"@Xpharma007","twitter_site":"@Xpharma007","twitter_misc":{"Written by":"xpharmanews","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\/#article","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\/"},"author":{"name":"xpharmanews","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05"},"headline":"Otsuka Pharmaceutical\uff1aVoyxactSibeprenlimab\u00a0was approved through the priority review process.","datePublished":"2026-06-05T16:16:35+00:00","dateModified":"2026-06-05T16:16:36+00:00","mainEntityOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\/"},"wordCount":204,"commentCount":0,"publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\/#primaryimage"},"thumbnailUrl":"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/otsuka.jpg","articleSection":["Approved News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/xpharma.com.cn\/index.php\/news\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\/#respond"]}]},{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\/","url":"https:\/\/xpharma.com.cn\/index.php\/news\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\/","name":"Otsuka Pharmaceutical\uff1aVoyxactSibeprenlimab\u00a0was approved through the priority review process. - Xpharma China","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/#website"},"primaryImageOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\/#primaryimage"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\/#primaryimage"},"thumbnailUrl":"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/otsuka.jpg","datePublished":"2026-06-05T16:16:35+00:00","dateModified":"2026-06-05T16:16:36+00:00","description":"Otsuka Pharmaceutical\uff1aVoyxactSibeprenlimab\u00a0was approved through the priority review process. - Xpharma China","breadcrumb":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/xpharma.com.cn\/index.php\/news\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\/#primaryimage","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/otsuka.jpg","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/otsuka.jpg","width":344,"height":146,"caption":"Otsuka Pharmaceutical"},{"@type":"BreadcrumbList","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/otsuka-pharmaceutical%ef%bc%9avoyxactsibeprenlimab-was-approved-through-the-priority-review-process\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9875","item":"https:\/\/xpharma.com.cn\/"},{"@type":"ListItem","position":2,"name":"Otsuka Pharmaceutical\uff1aVoyxactSibeprenlimab\u00a0was approved through the priority review process."}]},{"@type":"WebSite","@id":"https:\/\/xpharma.com.cn\/#website","url":"https:\/\/xpharma.com.cn\/","name":"Xpharma China - International Pharmaceutical wholesaler and retailer","description":"Xpharma China","publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/xpharma.com.cn\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/xpharma.com.cn\/#organization","name":"Xpharma China","url":"https:\/\/xpharma.com.cn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","width":679,"height":166,"caption":"Xpharma China"},"image":{"@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/61590027634719\/","https:\/\/x.com\/Xpharma007"]},{"@type":"Person","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05","name":"xpharmanews","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","caption":"xpharmanews"},"url":"https:\/\/xpharma.com.cn\/index.php\/author\/xpharmanews\/"}]}},"_links":{"self":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3761","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/comments?post=3761"}],"version-history":[{"count":1,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3761\/revisions"}],"predecessor-version":[{"id":3763,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3761\/revisions\/3763"}],"wp:attachment":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media?parent=3761"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/categories?post=3761"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/tags?post=3761"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}